23andMe Stock: Long-Term Promising (NASDAQ:ME)

gorodenkoff/iStock via Getty Images

Investment thesis

23andme (NASDAQ:ME) has proven to be a viable growth prospect thanks to its broad customer base and trusted brand. Despite some financial gaps and fierce competition in the field of genomic testing, 23andMe is

23andMe Finances

Yahoo finance

23andMe Peer Review

Yahoo finance

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top